Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Gastroenterology. 2021 Mar 9;160(7):2572–2584. doi: 10.1053/j.gastro.2021.01.233

Figure 2.

Figure 2.

Visual summary of the natural history of HCC that focus on key differences and challenges when designing studies to evaluate risk stratification vs early detection biomarkers. For risk stratification biomarkers, it is crucial to ensure that the patients are free of HCC. This includes a 2-year period to minimize the risk of undetectable microscopic HCC, which is a potential confounder in these studies. Used with permission from ©Mount Sinai Health System.